insights_auto
Outlook: 38.7% bullish·3.2% bearish
Go to analysischevron_right
JNJB34:BVMF
Johnson & Johnson BDR
R$86.55
arrow_upward
+1.52%(+1.30) 1D
Oct 20, 5:05:00 PM GMT-3 · BRL
search
All symbols
No data
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for JNJB34...
Open
R$85.25
High
R$87.00
Low
R$85.25
Mkt. cap
625.03B
Avg. vol.
8.31K
Volume
12.19K
52-wk high
R$96.19
52-wk low
R$64.68
Shares outstanding
2.41B
No. of employees
138K
Open
R$85.25
High
R$87.00
Low
R$85.25
Mkt. cap
625.03B
Avg. vol.
8.31K
Volume
12.19K
52-wk high
R$96.19
52-wk low
R$64.68
Shares outstanding
2.41B
No. of employees
138K
News stories
From web sources and news partners
Investing.com Canada
·
3 hours ago
TD Cowen reiterates Johnson & Johnson stock rating on Shockwave growth By Investing.com
Yahoo Finance
·
4 hours ago
Johnson & Johnson (JNJ): Are Its Medical Device Deals Paying Off?
Simply Wall Street
·
6 hours ago
Johnson & Johnson (JNJ) Stock Looks Reasonable As Crohns Drug Data Lands
About Johnson & Johnson BDR
CEOJoaquin Duato
Employees138K
FoundedJan 1886
HeadquartersNew Brunswick, New Jersey, United States
SectorPharmaceutical industry
Websitejnj.com
Last report
Oct 13, 2026
Fiscal period
Q3 2026
- Normalized EPS / Est. (USD)
- GAAP EPS / Est. (USD)
$2.59 / $2.52
+2.69%beat
arrow_upward
Revenue / Est. (USD)
25.40B / 25.38B
+0.07%beat
arrow_upward
Fiscal Q3 2026 earnings call
youtube_liveWaiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Income statement
Revenue
Net income
- Quarterly
- Annual
All values in USD | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 |
|---|---|---|---|---|
Revenue | 24.56B | 24.06B | 25.31B | 25.40B |
Cost of goods sold | 7.81B | 8.09B | 8.02B | 8.10B |
Cost of revenue | 7.81B | 8.09B | 8.02B | 8.10B |
Research and development expenses | 4.25B | 3.53B | 3.65B | 4.65B |
Total research and development expenses | - | - | - | - |
Selling, general, and admin expenses | 6.61B | 5.85B | 6.25B | 6.28B |
Operating expense | 10.86B | 9.38B | 9.91B | 10.94B |
Total operating expenses | 18.68B | 17.47B | 17.92B | 19.03B |
Operating income | 5.89B | 6.60B | 7.39B | 6.36B |
Other non operating income | 396.00M | -211.00M | 110.00M | -5.78B |
EBT including unusual items | 4.97B | 5.99B | 6.75B | 34.00M |
EBT excluding unusual items | 6.03B | 6.41B | 7.42B | 554.00M |
Income tax expense | -150.00M | 755.00M | 1.21B | -176.00M |
Effective tax rate | -3.02% | 12.60% | 17.98% | -517.65% |
Other operating expenses | - | - | - | - |
Net income | 5.12B | 5.24B | 5.53B | 210.00M |
Net profit margin | 20.83% | 21.76% | 21.86% | 0.83% |
Earnings per share | 2.46 | 2.70 | 2.90 | 2.59 |
Interest and investment income | 237.00M | 229.00M | 219.00M | - |
Interest expense | -214.00M | -272.00M | -281.00M | -31.00M |
Net interest expenses | 23.00M | -43.00M | -62.00M | -31.00M |
Depreciation and amortization charges | - | - | - | - |
EBITDA | 7.90B | 8.60B | 9.35B | 8.32B |
Gain or loss from assets sale | -132.00M | 12.00M | -55.00M | - |